Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
We investigated the clinical efficacy and tolerability of 45 mg/day mosapride, a selective 5-hydroxytryptamine type 4 (5-HT4) agonist, in an open-label study involving five patients with Parkinson's disease (PD) who had response fluctuations (RFs). 'On' time and motor function scores were determined, and gastric motility was measured by a radionuclide gastric emptying (GE) test, the most reliable quantitative method available. We found that mosapride therapy significantly shortened GE half-time, reduced RFs, and improved motor functions in all patients. There were no adverse reactions. We conclude that selective 5-HT4 agonist therapy is beneficial for patients with PD who have RFs.
Asai
Hirohide
H
Department of Neurology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. neurohiro@hotmail.com
Udaka
Fukashi
F
Hirano
Makito
M
Minami
Takeshi
T
Oda
Masaya
M
Kubori
Tamotsu
T
Nishinaka
Kazuto
K
Kameyama
Masakuni
M
Ueno
Satoshi
S
D000368:Aged; D000978:Antiparkinson Agents / Q000097:blood / Q000493:pharmacokinetics; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D005769:Gastrointestinal Motility / Q000502:physiology*; D006801:Humans; D007980:Levodopa / Q000097:blood / Q000493:pharmacokinetics; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D049268:Positron-Emission Tomography; D044422:Receptors, Serotonin, 5-HT4 / Q000187:drug effects*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D013270:Stomach / Q000000981:diagnostic imaging
D000978:Antiparkinson Agents; D001549:Benzamides; D009025:Morpholines; D017366:Serotonin Receptor Agonists; D044422:Receptors, Serotonin, 5-HT4; D007980:Levodopa; C062720:mosapride